Every 8-K that TriSalus Life Sciences Inc. (TLSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TLSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLSI filings page.
TriSalus Life Sciences reported second quarter 2026 revenue of $11.4 million from TriNav system sales, up 1.7% year over year, with gross margin improving to 86.8% from 83.9% as unit costs declined. Operating loss widened to $9.8 million, and net loss attributable to common stockholders was $9.2 million, or $0.16 per share.
Non-GAAP adjusted EBITDA loss was $7.1 million, reflecting higher sales and marketing spending to expand the commercial organization, partly offset by lower research and development and general and administrative expenses. Cash and cash equivalents reached $46.3 million, supported by an equity offering, and total stockholders’ equity improved to $6.6 million from a deficit of $33.9 million at December 31, 2025.
The company maintained full-year 2026 revenue guidance of $54–$57 million, representing 19%–26% growth over 2025, and highlighted progress in its Pressure-Enabled Drug Delivery platform, including new real-world evidence in liver cancer, the PEDIR study submission, and ongoing Phase 1 trials of investigational immunotherapy nelitolimod.
TriSalus Life Sciences, Inc. reported the results of its Annual Meeting of Stockholders. A total of 41,728,676 shares of common stock, representing 67.9% of outstanding shares, were present or represented, providing a solid quorum for the meeting’s business.
Stockholders elected Mary Szela and Gary Gordon as directors to serve three-year terms expiring at the 2029 annual meeting. The appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026 was also ratified by a wide margin.
On executive compensation matters, stockholders approved a three-year frequency for future advisory votes on named executive officer pay, and approved the current compensation of named executive officers on an advisory basis. Following the vote, the Board decided the company will hold say-on-pay votes every three years.
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million from its TriNav system, a 2.9% decrease from the same period in 2025, while gross margin improved to 86.2% from 83.7% as unit costs fell.
Operating loss widened slightly to $8.4 million, driven mainly by higher sales and marketing and stock-based compensation tied to commercial expansion. However, changes in the fair value of derivatives and earnout liabilities produced non-cash gains of $11.3 million, turning results into net income of $1.5 million, or $0.03 per share, versus a prior-year loss.
On a non-GAAP basis, adjusted EBITDA loss was $5.8 million, modestly higher than a year ago. The company raised $46.0 million in gross proceeds from an equity offering, ending March 31, 2026 with $56.6 million in cash and cash equivalents. Management revised 2026 revenue guidance to a range of $54 million to $57 million and highlighted ongoing clinical and commercial progress for its PEDD platform and nelitolimod program.
TriSalus Life Sciences, Inc. announced that Jodi Devlin has notified the company of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. The company previously appointed Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026, helping support continuity in its clinical and medical leadership.
TriSalus Life Sciences, Inc. appointed Richard Marshall, M.D. as Chief Medical Officer, effective June 29, 2026. He will move into this full-time role from his current position as Medical Director and will lead medical strategy, clinical development and evidence generation across the company’s oncology programs.
Under his offer letter, Dr. Marshall will receive an annual base salary of $525,000, a $250,000 sign-on bonus, and will be eligible for an annual bonus of up to 50% of base salary based on Board-determined goals. Following his start date, the Board will be asked to grant him 120,000 stock options and 60,000 restricted stock units, with further annual equity grants possible under the Equity Incentive Plan.
The accompanying press release highlights Dr. Marshall’s background in interventional oncology and his role in supporting TriSalus’ Pressure-Enabled Drug Delivery platform, TriNav devices and investigational immunotherapy nelitolimod as the company advances treatments for solid tumors.
TriSalus Life Sciences reported strong growth for 2025 but remained unprofitable. Revenue from the TriNav system reached $45.2 million for the year, up 53% from 2024, with fourth quarter revenue of $13.2 million, a 60% year-over-year increase and 14% sequential growth.
Full-year gross profit rose to $38.2 million, though gross margin edged down to 84.6%, reflecting launch-related manufacturing inefficiencies. Operating loss narrowed to $26.9 million, and adjusted EBITDA loss improved to $17.2 million. Net loss attributable to common stockholders expanded to $69.7 million, mainly due to preferred stock conversion-related items.
Cash and cash equivalents were $20.4 million as of December 31, 2025, and subsequent to year-end the company raised $46 million in gross proceeds via a public offering. Management reaffirmed 2026 revenue guidance of $60–62 million and highlighted continued commercial adoption of TriNav, higher gross margins in Q4 2025, and ongoing investments in clinical studies and new PEDD-based products.
TriSalus Life Sciences, Inc. has entered into an underwriting agreement for a public offering of 9,756,100 shares of its common stock at $4.10 per share. The company also granted underwriters a 30-day option to buy up to 1,463,415 additional shares to cover over-allotments.
Gross proceeds are expected to be about $40.0 million, with estimated net proceeds of approximately $37.0 million without exercising the option, or about $42.64 million if the option is fully exercised. TriSalus plans to use the cash for general corporate purposes, including capital spending, working capital, and administrative costs.
The deal is being made under an effective Form S-3 shelf registration, with Lake Street Capital Markets acting as sole book-runner. The offering is expected to close around February 23, 2026, and the company, its officers, directors, and a key securityholder have agreed to 90-day lock-up periods.
TriSalus Life Sciences, Inc. announced a board change, with Dr. Arjun “JJ” Desai resigning as a director effective February 3, 2026. His resignation is stated to be unrelated to any disagreement over the company’s operations, policies, or practices.
The company appointed veteran healthcare investor Michael P. Stansky to its Board of Directors effective February 4, 2026. He will serve on the Audit Committee, Compensation Committee, and Science and Technology Committee. TriSalus highlighted his 40 years of investment management and healthcare experience, including senior roles at Tudor Investment Corporation and Wellington Management.
TriSalus Life Sciences, Inc. filed a current report to note that it issued a press release with preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with 2026 revenue guidance. The company attached this press release as Exhibit 99.1 and incorporated it by reference for informational purposes. The report also clarifies that the press release and related information are being furnished rather than filed, which limits their exposure to certain securities law liabilities.
TriSalus Life Sciences (TLSI) furnished a press release providing a business update and financial results for the quarter ended September 30, 2025.
The release is attached as Exhibit 99.1 and, along with the Inline XBRL cover file (Exhibit 104), is furnished and not deemed filed under Section 18, and is incorporated by reference only if specifically referenced.
TriSalus Life Sciences, Inc. reported that board member Sean Murphy resigned from the company’s Board of Directors and its Science and Technology Committee, effective September 30, 2025. The company stated that his resignation is not due to any disagreement with TriSalus on its operations, policies, or practices. The filing confirms the change is limited to his board and committee roles and provides no indication of broader operational or strategic issues.
TriSalus Life Sciences, Inc. increased annual compensation for its Chief Financial Officer, David Patience, as approved by the Compensation Committee. His annual base salary rose from $450,000 under his May 27, 2025 employment agreement to $550,000, effective immediately.
In addition, the Compensation Committee granted Mr. Patience stock options to purchase 249,899 shares of common stock at an exercise price of $5.11 per share. These options vest only if the company achieves or exceeds $75 million of revenue over any twelve consecutive calendar month period ending on or before December 31, 2027, tying his equity incentive to a specific revenue performance goal.
TriSalus Life Sciences, Inc. filed a current report to note that on August 12, 2025 it issued a press release providing a business update and announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is treated as furnished, not filed, under securities laws, which limits its use in certain types of investor lawsuits and in other company filings unless specifically incorporated by reference.
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) filed an 8-K to announce the launch of a dual exchange offer and consent solicitation aimed at retiring its outstanding Series A Convertible Preferred Stock. Holders who tender will receive a number of common shares equal to the sum of the preferred share’s Liquidation Preference plus all accrued dividends through August 10, 2027, divided by $4.00 per share. The company is offering up to 11,860,206 new common shares in total.
Concurrently, TriSalus seeks holder approval to amend the Certificate of Designations so that any preferred shares not exchanged can be mandatorily converted at a ratio that is 11.3 % less favorable than the voluntary exchange ratio. Investors representing approximately 55 % of outstanding preferred shares have already executed Tender and Support Agreements, effectively securing majority backing for both the exchange and the amendment, provided other conditions are met.
The offer began on June 23, 2025 and is scheduled to expire one minute after 11:59 p.m. EST on July 23, 2025, unless extended. Preferred holders may withdraw tenders any time before expiration. The transaction is being effected through a Form S-4 registration statement and Schedule TO filed the same day; investors are urged to review these filings for full terms and risk factors.
If completed, the exchange would eliminate a cumulative dividend obligation, simplify the capital structure, and remove an overhang that could impede future financing. However, it will also dilute existing common shareholders by up to roughly 25 % of the current basic share count, subject to final participation levels.